company background image

VistaGen Therapeutics NasdaqCM:VTGN Stock Report

Last Price


Market Cap







06 Oct, 2022


Company Financials +
VTGN fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health4/6

VTGN Stock Overview

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).

VistaGen Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for VistaGen Therapeutics
Historical stock prices
Current Share PriceUS$0.16
52 Week HighUS$2.69
52 Week LowUS$0.14
1 Month Change-6.10%
3 Month Change-83.14%
1 Year Change-93.94%
3 Year Change-85.60%
5 Year Change-88.11%
Change since IPO-99.68%

Recent News & Updates

Sep 08

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

VistaGen Therapeutics (NASDAQ:VTGN) on Thursday said an independent group of biostatisticians recommended continuing its second phase 3 trial evaluating its nasal spray PH94B for the treatment of anxiety in adults with social anxiety disorder. The interim analysis of data from the late-stage trial, called PALISADE-2, concluded that the study should continue as planned, VTGN said in a statement. The independent biostatisticians reviewed unblinded data from the 140 subjects who completed the trial before VistaGen (VTGN) paused enrollment in July. The company noted that it did not have access to the unblinded data. VTGN said it would continue the study as recommended by the biostatisticians without any adjustment to its expected size of 208 subjects. Topline results from the late-stage trial is expected in H1 2023. VTGN stock +5.7% to $0.17 in morning trading.

Shareholder Returns

VTGNUS BiotechsUS Market

Return vs Industry: VTGN underperformed the US Biotechs industry which returned -19.3% over the past year.

Return vs Market: VTGN underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is VTGN's price volatile compared to industry and market?
VTGN volatility
VTGN Average Weekly Movement29.3%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: VTGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 29% a week.

Volatility Over Time: VTGN's weekly volatility has increased from 17% to 29% over the past year.

About the Company

199838Shawn Singh

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders.

VistaGen Therapeutics Fundamentals Summary

How do VistaGen Therapeutics's earnings and revenue compare to its market cap?
VTGN fundamental statistics
Market CapUS$32.47m
Earnings (TTM)-US$60.38m
Revenue (TTM)US$1.06m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VTGN income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$1.06m
Other ExpensesUS$61.44m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.29
Gross Margin100.00%
Net Profit Margin-5,669.78%
Debt/Equity Ratio2.3%

How did VTGN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is VTGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTGN?

Other financial metrics that can be useful for relative valuation.

VTGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does VTGN's PS Ratio compare to its peers?

VTGN PS Ratio vs Peers
The above table shows the PS ratio for VTGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14.8x
MRKR Marker Therapeutics
CASI CASI Pharmaceuticals
SLS SELLAS Life Sciences Group
AGLE Aeglea BioTherapeutics
VTGN VistaGen Therapeutics

Price-To-Sales vs Peers: VTGN is expensive based on its Price-To-Sales Ratio (30.5x) compared to the peer average (14.8x).

Price to Earnings Ratio vs Industry

How does VTGN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: VTGN is expensive based on its Price-To-Sales Ratio (30.5x) compared to the US Biotechs industry average (14x)

Price to Sales Ratio vs Fair Ratio

What is VTGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.5x
Fair PS Ratio42.9x

Price-To-Sales vs Fair Ratio: VTGN is good value based on its Price-To-Sales Ratio (30.5x) compared to the estimated Fair Price-To-Sales Ratio (42.9x).

Share Price vs Fair Value

What is the Fair Price of VTGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VTGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VTGN's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is VistaGen Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VTGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VTGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VTGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VTGN's revenue (68.6% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: VTGN's revenue (68.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VTGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has VistaGen Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VTGN is currently unprofitable.

Growing Profit Margin: VTGN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: VTGN is unprofitable, and losses have increased over the past 5 years at a rate of 30.1% per year.

Accelerating Growth: Unable to compare VTGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: VTGN has a negative Return on Equity (-129.84%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is VistaGen Therapeutics's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VTGN's short term assets ($55.0M) exceed its short term liabilities ($8.9M).

Long Term Liabilities: VTGN's short term assets ($55.0M) exceed its long term liabilities ($3.7M).

Debt to Equity History and Analysis

Debt Level: VTGN has more cash than its total debt.

Reducing Debt: VTGN's debt to equity ratio has reduced from 13.6% to 2.3% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTGN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VTGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.3% each year

Discover healthy companies


What is VistaGen Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

VistaGen Therapeutics Dividend Yield vs Market
How does VistaGen Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (VistaGen Therapeutics)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (VistaGen Therapeutics)n/a

Notable Dividend: Unable to evaluate VTGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VTGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VTGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VTGN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VTGN has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Shawn Singh (59 yo)





Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....

CEO Compensation Analysis

Shawn Singh's Compensation vs VistaGen Therapeutics Earnings
How has Shawn Singh's remuneration changed compared to VistaGen Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022US$1mUS$563k


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021US$1mUS$511k


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020US$934kUS$498k


Dec 31 2019n/an/a


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019US$951kUS$466k


Dec 31 2018n/an/a


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018US$1mUS$425k


Dec 31 2017n/an/a


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017US$1mUS$385k


Dec 31 2016n/an/a


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016US$2mUS$348k


Compensation vs Market: Shawn's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: VTGN's management team is seasoned and experienced (6 years average tenure).

Board Members

Experienced Board: VTGN's board of directors are considered experienced (6.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: VTGN insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqCM:VTGN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Aug 22BuyUS$35,740Jerry GinIndividual200,000US$0.18
17 Aug 22BuyUS$103,200Shawn SinghIndividual600,000US$0.17
17 Aug 22BuyUS$50,910Reid AdlerIndividual300,000US$0.17
12 Jul 22SellUS$53,400VR Adviser, LLCCompany60,000US$0.89

Ownership Breakdown

What is the ownership structure of VTGN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,692,5120.8%
Hedge Funds13,049,0796.3%
VC/PE Firms50,361,16524.3%
General Public63,627,33230.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.

Top Shareholders

Top 25 shareholders own 65.51% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
VR Adviser, LLC
New Enterprise Associates, Inc.
OrbiMed Advisors LLC
Commodore Capital LP
BlackRock, Inc.
11,716,039$1.8m-0.14%no data
Acuta Capital Partners LLC
The Vanguard Group, Inc.
9,967,146$1.6m7.54%no data
Franklin Resources, Inc.
9,448,954$1.5m-4.95%no data
Nicholas Investment Partners, L.P.
State Street Global Advisors, Inc.
3,895,398$611.6k7.91%no data
Geode Capital Management, LLC
3,375,473$529.9k4.58%no data
Sphera Funds Management Ltd
MAI Capital Management, LLC
Norges Bank Investment Management
1,930,783$303.1k0%no data
Northern Trust Global Investments
1,589,048$249.5k-2.81%no data
EPIQ Partners, LLC
Citadel Advisors LLC
1,290,983$202.7k23.56%no data
Millennium Management LLC
872,959$137.1k-29.62%no data
Renaissance Technologies LLC
830,612$130.4k-29.52%no data
Soleus Capital Management, L.P.
Shawn Singh
780,232$122.5k332.9%no data
BNY Mellon Asset Management
714,140$112.1k-7.12%no data
Abaris Investment Management AG
Teachers Insurance and Annuity Association-College Retirement Equities Fund
593,660$93.2k-2.57%no data
Charles Schwab Investment Management, Inc.
540,747$84.9k-2.25%no data

Company Information

VistaGen Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: VistaGen Therapeutics, Inc.
  • Ticker: VTGN
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$32.473m
  • Shares outstanding: 206.84m
  • Website:

Number of Employees


  • VistaGen Therapeutics, Inc.
  • 343 Allerton Avenue
  • South San Francisco
  • California
  • 94080
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VTGNNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDMay 2011

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.